Patients suffering from mesothelioma, lung cancer, and other solid tumors may be eligible to participate in clinical trials at the National Cancer Institute (NCI) in Bethesda Maryland involving the use of immunotherapy agents which target the tumor antigen mesothelin. Dr. Raffitt Hassan, M.D., is the head of the Solid Immunotherapy Section and is currently conducting clinical trials involving two different immunotherapy agents for the treatment of malignant mesothelioma. The first trial, referred to as a Phase 1B study, is to evaluate the safety and immune response to the IV infusion of CRS-207 combined with Pemetrexed and Cisplatin in patients with pleural mesothelioma. The second trial is a pilot study of Pentostatin plus Cyclophosphamide Immune Depletion to decrease immunogenicity of SS1P in patients with mesothelioma. Like the first trial the agent, Pentostatin is administered by IV infusion. Both trials are being conducted at NCI in Bethesda by Dr. Hassan. For further information contact NCI and Dr. Hassan at www.nih.gov/.